Fluoxetine

Generic Name: Fluoxetine

Brand Names: Prozac, Sarafem, Symbyax

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈F_₃NO

CAS Number: 54910-89-3

Unique Ingredient Identifier: 01K63SUP8D

Background: Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication: Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...

Associated Conditions: Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)

Associated Therapies: Maintenance therapy

Clinical Trials

Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?

Not Applicable

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2005-09-21

Last Posted Date: 2013-11-11

Lead Sponsor: Emory University

Target Recruit Count: 80

Registration Number: NCT00208897

Locations: 🇺🇸
Department of Psychiatry and Behavioral Sciences, Atlanta, Georgia, United States

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

Phase 4

Completed

Conditions: Depression, Bipolar

First Posted Date: 2005-09-19

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 150

Registration Number: NCT00191399

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Santurce, Puerto Rico
🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hato Rey, Puerto Rico

Early Intervention With Fluoxetine in Autism

Phase 2

Completed

Conditions: Autistic Disorder

Interventions: Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2005-09-16

Last Posted Date: 2014-03-26

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 18

Registration Number: NCT00183339

Locations: 🇺🇸
University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence

Phase 2

Completed

Conditions: Depressive Disorder, Major
Cannabis Abuse

Interventions: Drug: Fluoxetine
Other: Placebo

First Posted Date: 2005-09-08

Last Posted Date: 2013-06-24

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 70

Registration Number: NCT00149643

Locations: 🇺🇸
Department of Psychiatry, Pittsburgh, Pennsylvania, United States

Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts

Not Applicable

Completed

Conditions: Cocaine-Related Disorders
Opioid-Related Disorders

First Posted Date: 2005-09-02

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 220

Registration Number: NCT00142779

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia

Phase 3

Completed

Conditions: Fibromyalgia
Juvenile Primary Fibromyalgia Syndrome (JPFS)

Interventions: Drug: Fluoxetine

First Posted Date: 2005-06-27

Last Posted Date: 2017-02-10

Lead Sponsor: University of Cincinnati

Target Recruit Count: 6

Registration Number: NCT00115804

Locations: 🇺🇸
Women's Health Research Program, Cincinnati, Ohio, United States

Fluoxetine as a Quit Smoking AID for Depression Prone

Not Applicable

Completed

Conditions: Heart Diseases
Cardiovascular Diseases

First Posted Date: 2005-06-10

Last Posted Date: 2016-02-18

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00113737

Treatment of Adolescent Suicide Attempters (TASA)

Phase 2

Completed

Conditions: Suicide, Attempted
Depression

First Posted Date: 2004-03-26

Last Posted Date: 2020-06-22

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 120

Registration Number: NCT00080158

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸
New York University Child Study Center, New York, New York, United States

and more 3 locations